Skip to main content
Study shows positive results for St. Jude's Amplatzer device

A study presented at the European Association of Percutaneous Cardiovascular Interventions' annual congress showed percutaneous left atrial appendage closure using St. Jude Medical's Amplatzer device in patients with nonvalvular atrial fibrillation had a lower rate of the composite primary efficacy endpoint, consisting of systemic embolism, stroke and cardiovascular or unexplained mortality, than that of oral anticoagulation. The device therapy also led to a lower rate of the composite safety endpoint, composed of major bleeding and major procedural adverse events.

Full Story: